Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma.
Mª Reyes García-de-la-FuenteMaria SantacanaJoan VerdaguerFelip VilardellEloi GaríJosep Manel CasanovaPublished in: The Australasian journal of dermatology (2020)
Ingenol mebutate gel produces a transient immuno-inflammatory response and an important necrosis reaction in BCCs. Larger studies will be required to determine the maximum effective tolerated dose of ingenol mebutate gel for BCC.